Rainbow Childrens Medicare Q1 Results: Net Profit Rises to ₹606M, Revenue Up 33% YoY
Rainbow Children's Medicare posted Q1 consolidated net profit of ₹606 million, up from ₹534 million year-on-year, as revenue climbed to ₹4.7 billion from ₹3.53 billion. EBITDA rose to ₹1.35 billion from ₹1 billion, though EBITDA margin dipped to 28.66% from 29.38%. The company also announced two hospital acquisitions and a senior management appointment during the period.

*this image is generated using AI for illustrative purposes only.
Rainbow Children's Medicare Limited reported a consolidated net profit of ₹606 million for Q1, up from ₹534 million in the year-ago period. Consolidated revenue from operations rose to ₹4.7 billion from ₹3.53 billion year-on-year, reflecting strong demand across its healthcare network. The company also posted a standalone net profit of ₹527.06 million, compared to ₹517.20 million in the prior year period.
The results were reviewed by statutory auditors S.R. Batliboi & Associates LLP and approved by the Board of Directors on July 30, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board also approved the elevation of Mr. Anshuman Jaiswal from Group Head – Legal to Chief Legal Officer, designating him as Senior Management Personnel with immediate effect.
Financial Performance
Consolidated EBITDA came in at ₹1.35 billion, compared to ₹1 billion in the year-ago period, while EBITDA margin stood at 28.66% versus 29.38% year-on-year, indicating modest margin compression despite strong top-line growth. Consolidated total income reached ₹4,826.95 million, supported by other income of ₹127.10 million. Total expenses stood at ₹3,987.42 million, with professional fees to doctors rising to ₹1,238.19 million from ₹917.58 million in the prior year period. Profit before tax was ₹839.53 million, against ₹713.74 million in the corresponding quarter of the previous year.
The following table summarises key consolidated financial metrics for the quarter:
| Metric: | Q1FY26 | Q1FY25 | Change (YoY) |
|---|---|---|---|
| Revenue from Operations: | ₹4.7 billion | ₹3.53 billion | Higher |
| Net Profit After Tax: | ₹606 million | ₹534 million | Higher |
| EBITDA: | ₹1.35 billion | ₹1 billion | Higher |
| EBITDA Margin: | 28.66% | 29.38% | Lower |
Standalone revenue from operations increased 22.6% to ₹4,105.47 million. Standalone profit before tax was ₹705.41 million, compared to ₹688.20 million in the prior year period. Basic earnings per share on a standalone basis rose to ₹5.20 from ₹5.09 in the prior year period.
Strategic Developments
Subsequent to the quarter end, the company executed definitive transaction documents for a new children and women's hospital at Malad, Mumbai, through its wholly owned subsidiary Rainbow Women & Children's Hospital Private Limited. The transaction is expected to complete in the quarter ended September 30, 2026.
Additionally, Rainbow Children's Medicare Limited signed a Partnership Interest and Contribution Transfer Agreement to acquire a 64% stake in Super Prime Medical Care LLP for an aggregate consideration of ₹198 million. This acquisition targets a running children's hospital in Nellore, Andhra Pradesh, with completion also expected in the quarter ended September 30, 2026.
Key Takeaways
The slight contraction in EBITDA margin — from 29.38% to 28.66% — alongside robust revenue growth underscores margin pressure from higher professional fees to doctors, which grew significantly year-on-year. While patient volumes are expanding rapidly, the cost structure is scaling proportionally, requiring careful management of doctor compensation relative to service pricing to sustain profitability gains.
Historical Stock Returns for Rainbow Childrens Medicare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.60% | +2.06% | +8.19% | +28.36% | -0.30% | +237.76% |
How will the integration of the new Malad hospital and the Nellore acquisition impact Rainbow Children's Medicare's EBITDA margins in the short term, given the current pressure from rising doctor fees?
What specific strategies is management implementing to control the year-on-year surge in professional fees to doctors without compromising patient volume growth?
Will the capital expenditure required for the Malad and Nellore expansions necessitate external financing, and how might this affect the company's debt-to-equity ratio?


































